Isobutylamine → tert-butyl (4S)-4-[4-((2-methylpropyl)methylcarbamoyl)piperidin-1-yl]azepane-1-carboxylate
반응식
CO[C:3]([CH:5]1[CH2:10][CH2:9][N:8]([C@H:11]2[CH2:17][CH2:16][CH2:15][N:14]([C:18]([O:20][C:21]([CH3:24])([CH3:23])[CH3:22])=[O:19])[CH2:13][CH2:12]2)[CH2:7][CH2:6]1)=[O:4].[CH2:25]([NH2:29])[CH:26]([CH3:28])[CH3:27].[CH3:30]N(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C>CN(C=O)C>[CH3:27][CH:26]([CH3:28])[CH2:25][N:29]([CH3:30])[C:3]([CH:5]1[CH2:6][CH2:7][N:8]([C@H:11]2[CH2:17][CH2:16][CH2:15][N:14]([C:18]([O:20][C:21]([CH3:23])([CH3:22])[CH3:24])=[O:19])[CH2:13][CH2:12]2)[CH2:9][CH2:10]1)=[O:4]참가 물질
반응물 4
생성물 1
시약·촉매·용매 1
실험 절차
tert-butyl (4S)-4-[4-(methoxycarbonyl)piperidin-1-yl]azepane-1-carboxylate (0.3 g, 0.92 mmol) was dissolved in DMF (4 mL) and isobutylamine (0.14 g, 0.18 mL, 1.84 mmol), HATU (0.53 g, 1.38 mmol) and DIPEA (0.36 g, 0.48 mL, 2.76 mmol) were added. The reaction mixture was stirred at rt for 48 h and the solvents were removed in vacuo. The residue was partitioned between DCM and sat. NaHCO3 sol., the organic layer was washed with sat. NaCl sol. and dried (MgSO4). The solvents were removed in vacuo, and the residue was purified by column chromatography (normal phase, [Biotage SNAP cartridge KP-sil 10 g, 40-63 μm, 60 Å, 12 mL per min, gradient 0% to 10% MeOH in DCM]) to give tert-butyl (4S)-4-[4-((2-methylpropyl)methylcarbamoyl)piperidin-1-yl]azepane-1-carboxylate (0.12 g, 35%) as a pale yellow gum.
후처리
- customthe solvents were removed in vacuo
- customThe residue was partitioned between DCM and sat. NaHCO3 sol.
- washthe organic layer was washed with sat. NaCl sol.
- dry with materialdried (MgSO4)
- customThe solvents were removed in vacuo
- customthe residue was purified by column chromatography (normal phase, [Biotage SNAP cartridge KP-sil 10 g, 40-63 μm, 60 Å, 12 mL per min, gradient 0% to 10% MeOH in DCM])
출처 및 근거
- ORD 기록
- ord-d07718dcd4a948549a633147b7ea0660
- 출처 데이터셋
- uspto-grants-2015_11
- 특허 번호
- US09187451B2
반응 노트
불러오는 중…